| 注册
首页|期刊导航|中国临床药理学杂志|奥氮平片联合丙戊酸镁缓释片治疗青少年抑郁患者的临床研究

奥氮平片联合丙戊酸镁缓释片治疗青少年抑郁患者的临床研究

崔佩瑾 王钥 曹茂林 张翼飞 房亮

中国临床药理学杂志2024,Vol.40Issue(19):2817-2821,5.
中国临床药理学杂志2024,Vol.40Issue(19):2817-2821,5.DOI:10.13699/j.cnki.1001-6821.2024.19.012

奥氮平片联合丙戊酸镁缓释片治疗青少年抑郁患者的临床研究

Clinical trial of olanzapine tablets combined with magnesium valproate sustained-release tablets in the treatment of adolescent patients with depression

崔佩瑾 1王钥 2曹茂林 3张翼飞 2房亮1

作者信息

  • 1. 重庆医科大学附属永川医院神经内科,重庆 402160
  • 2. 重庆医科大学附属永川医院儿科,重庆 402160
  • 3. 重庆医科大学附属永川医院全科医学科,重庆 402160
  • 折叠

摘要

Abstract

Objective To observe the clinical efficacy and safety of olanzapine tablets combined with magnesium valproate sustained-release tablets in the treatment of adolescent depressed patients.Methods Adolescents with depression were divided into control group and treatment group by simple random method.The control group was treated with oral olanzapine tablets with 5 mg·d-1 as the starting dose.After 1 week of treatment,the drug dose was adjusted according to the symptoms and kept within 20 mg·d-1.The treatment group was given oral magnesium valproate sustained-release tablet combined treatment on the basis of the control group,with 0.5 g as the initial dose,and the maximum dose was adjusted according to clinical symptoms after 1 week of treatment,and the maximum dose was no more than 1 g·d-1.Both groups were treated for 12 weeks.The clinical efficacy,excitatory amino acid(EAA),connectin level,intestinal fatty acid binding protein(Ⅰ-FABP),Hamilton depression scale(HAMD),Bech-Rafaelsen Mania Rating Scale(BRMS)and safety of the two groups were compared.Results Sixty-three cases were included in the treatment group and control group,respectively.After treatment,the total effective rates of the treatment group and the control group were 92.06%(58 cases/63 cases)and 79.37%(50 cases/63 cases),respectively,and the difference was statistically significant(P<0.05).After treatment,the levels of EAA in the treatment group and the control group were(29.98±3.44)and(27.97±3.88)μg·mL-1;the levels of zonulin were(189.45±19.56)and(182.33±19.89)ng·mL-1;the levels of Ⅰ-FABP were(99.27±9.13)and(103.84±9.36)pg·mL-1,respectively;the HAMD scores of the treatment group and the control group were 9.88±1.03 and 10.74±1.95;the BRMS scores were 5.08±0.32 and 5.32±0.51,respectively.Compared with the control group,the differences of above indexes in the treatment group were statistically significant(all P<0.05).The main adverse drug reactions in the two groups were weight gain,dry mouth,and drowsiness.The total incidences of adverse drug reactions in the treatment group and the control group were 12.70%and 15.87%,respectively,and the difference was not statistically significant(P>0.05).Conclusion Olanzapine tablets combined with magnesium valproate sustained-release tablets can effectively increase plasma Ⅰ-FABP,EAA,and zonulin levels in adolescent depressed patients,and improve HAMD and BRMS scores,with good safety.

关键词

奥氮平片/丙戊酸镁缓释片/青少年抑郁/汉密尔顿抑郁量表/躁狂现象

Key words

olanzapine tablet/magnesium valproate sustained-release tablet/adolescent depression/Hamilton depression scale/manic phenomena

分类

医药卫生

引用本文复制引用

崔佩瑾,王钥,曹茂林,张翼飞,房亮..奥氮平片联合丙戊酸镁缓释片治疗青少年抑郁患者的临床研究[J].中国临床药理学杂志,2024,40(19):2817-2821,5.

中国临床药理学杂志

OA北大核心CSTPCD

1001-6821

访问量0
|
下载量0
段落导航相关论文